Real-world efficacy of Omalizumab against chronic inducible and spontaneous urticaria

Summaries 3 min 309

Font Size

Created On: 19/08/2022

In an attempt to assess the effectiveness of Omalizumab in people with chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU), a real-world study was conducted.

See All

Key take away

Omalizumab 150 mg considerably reduced symptoms and was effective against both chronic spontaneous urticaria and chronic inducible urticaria.

Background

In an attempt to assess the effectiveness of Omalizumab in people with chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU), a real-world study was conducted.

Method

This study was carried out in 81 patients (age ≥ 19 years) including 52 and 29 with isolated CSU and CIndU, respectively, who were managed with 150 mg of omalizumab at least thrice every four weeks.

At baseline, week 4, and week 12, retrospective evaluation of Urticaria Activity Score 7 (UAS7) was performed.

Result

With only one dosage, 150 mg Omalizumab dramatically reduced UAS7 in individuals with CIndU and CSU. From weeks 4 to 12, both groups' UAS7 scores continued to decrease substantially, as shown below:

Despite there being no discernible difference in treatment efficacy between the two groups, the symptoms of CSU subjects were reported to recover more quickly. Furthermore, the number of cyclosporine and antihistamine tablets prescribed daily decreased more noticeably in this patient group. Additionally, individuals with CSU had a greater response rate, and a lower UAS7 score between week 12 and baseline.

Omalizumab could work slightly better against CSU than it does against CIndU. Concerning subtypes of CIndU, dermatographic urticaria patients had the highest response rates, which suggested that Omalizumab had the strongest effects. This condition was also related to the highest decrease in the UAS7 score. In non-responders compared to responders, the duration of chronic urticaria was longer. On the other hand, responders had considerably greater baseline immunoglobulin E levels.

Conclusion

Hence, the monoclonal antibody Omalizumab was associated with a considerable reduction in UAS7 in both CSU and CIndU patients. It may be slightly more efficacious against CSU than against CIndU.